PMID- 3895877
OWN - NLM
STAT- MEDLINE
DCOM- 19850909
LR  - 20190626
IS  - 0002-8703 (Print)
IS  - 0002-8703 (Linking)
VI  - 110
IP  - 2
DP  - 1985 Aug
TI  - A cooperative multicenter study of captopril in congestive heart failure: 
      hemodynamic effects and long-term response.
PG  - 439-47
AB  - The acute hemodynamic effects, long-term clinical efficacy, and safety of the 
      oral angiotensin-converting enzyme inhibitor, captopril, were assessed in a 
      multicenter cooperative study of 124 patients with heart failure resistant to 
      digitalis and diuretics. The cardiac status of most patients was deteriorating 
      prior to the study. Favorable acute hemodynamic effects consistently occurred 
      with captopril. Maximal mean percentage increases in cardiac index, stroke index, 
      and stroke work index were, respectively, 35%, 44%, and 34%. Systemic and 
      pulmonary vascular resistances were each decreased by approximately 40%, as were 
      the filling pressures of the right and left heart. Infusion of nitroprusside in 
      some of the same patients to an end point of a pulmonary capillary wedge pressure 
      of 12 to 18 mm Hg (equivalent to that after captopril) revealed no significant 
      difference in the effect of either drug on the other hemodynamic parameters. 
      Recatheterization after 8 weeks of captopril therapy revealed sustained 
      hemodynamic changes. Significant and sustained improvements in clinical status 
      were observed in most patients as measured by changes in New York Heart 
      Association (NYHA) functional classification and exercise tolerance times. 
      Seventy-nine percent of patients for whom there were adequate NYHA class data 
      improved. Twenty percent remained unchanged and 1% deteriorated. Those patients 
      who had both pretreatment and post-treatment exercise stress testing exhibited a 
      highly significant mean increase in exercise tolerance times of 34% (317 +/- 32 
      seconds pretreatment to 425 +/- 34 seconds, final measurement). There was no 
      evidence of tachyphylaxis over an 18-month period.(ABSTRACT TRUNCATED AT 250 
      WORDS)
FAU - Chatterjee, K
AU  - Chatterjee K
FAU - Parmley, W W
AU  - Parmley WW
FAU - Cohn, J N
AU  - Cohn JN
FAU - Levine, T B
AU  - Levine TB
FAU - Awan, N A
AU  - Awan NA
FAU - Mason, D T
AU  - Mason DT
FAU - Faxon, D P
AU  - Faxon DP
FAU - Creager, M
AU  - Creager M
FAU - Gavras, H P
AU  - Gavras HP
FAU - Fouad, F M
AU  - Fouad FM
AU  - et al.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 169D1260KM (Nitroprusside)
RN  - 9DLQ4CIU6V (Proline)
RN  - 9G64RSX1XD (Captopril)
RN  - EC 3.4.23.15 (Renin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Blood Pressure/drug effects
MH  - Captopril/adverse effects/pharmacology/*therapeutic use
MH  - Cardiac Output/drug effects
MH  - Clinical Trials as Topic
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/*drug therapy/physiopathology
MH  - Hemodynamics/*drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nitroprusside/pharmacology
MH  - Proline/*analogs & derivatives
MH  - Renin/blood
MH  - Time Factors
MH  - Vascular Resistance/drug effects
EDAT- 1985/08/01 00:00
MHDA- 1985/08/01 00:01
CRDT- 1985/08/01 00:00
PHST- 1985/08/01 00:00 [pubmed]
PHST- 1985/08/01 00:01 [medline]
PHST- 1985/08/01 00:00 [entrez]
AID - 0002-8703(85)90167-X [pii]
AID - 10.1016/0002-8703(85)90167-x [doi]
PST - ppublish
SO  - Am Heart J. 1985 Aug;110(2):439-47. doi: 10.1016/0002-8703(85)90167-x.